Willy O.

Willy O. has a solid work experience, with their most recent role being a Project and Business Development Manager at Integra Therapeutics since February 2023. Prior to that, they worked as an Investment Analyst at Andera Partners from June 2022 to February 2023. Willy also gained experience as a Venture Capital & Growth Fellow at Gilde Healthcare from January 2022 to April 2022. Willy's earlier experience includes working as a PhD Student at Doctoral School of Biomedical Sciences - KU Leuven from March 2017 to March 2022, as well as a Research Assistant at Uniklinik Köln from May 2016 to January 2017 and at Karolinska Institutet from February 2015 to May 2016.

Willy O. started their education in 2009 at Universidade de Coimbra, where they pursued a degree in Pharmaceutical Sciences. Willy completed their studies in 2014 and obtained a PharmD.

Afterward, Willy O. embarked on a more advanced academic path and joined KU Leuven in 2017. In this institution, they pursued a Doctor of Philosophy (PhD) degree in Biological and Biomedical Sciences. Willy'sdoctoral education extended from 2017 to 2022.

In addition to their formal education, Willy O. also obtained additional certifications. In March 2019, they completed a course titled "Introduction to RNA-seq & Functional Interpretation" at the European Bioinformatics Institute | EMBL-EBI. In December 2015, they achieved a TOEFL iBT score of 116, indicating their competency in English language proficiency, through an assessment administered by ETS Global B.V. Furthermore, in May 2016, they participated in a practical training course and workshop titled "Derivation and Culture of hiPSCs" conducted by the UK Stem Cell Bank.